RE: The Holy Grail RNS Price Paradox question?8 Apr 2021 16:29
Nostra, it's easy for everyone, even those committed to AVCT, to get distracted on the issue of LFTs. One comment was made, by Starbright, which recognises this.
"Avacta has other opportunities that may - in time - generate huge value for shareholders." That's understatement for the fact that Avacta's efforts in LFTs are not its real business, that's in cancer and maybe other treatments not yet envisaged which are a longer term thing. So maybe as a trader you don't look at that, but for investors prepared to stay for the journey, that's where much of the value lies which won't yet be baked in to the price.